Human Fusion Protein for Targeted Cancer Treatment
Author Information
Author(s): de Graaf M, Boven E, Oosterhoff D, van der Meulen-Muileman I H, Huls G A, Gerritsen W R, Haisma H J, Pinedo H M
Primary Institution: Vrije Universiteit Medical Centre
Hypothesis
Can a fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein selectively activate a non-toxic prodrug at tumor sites?
Conclusion
The C28-GUSh fusion protein can effectively convert a non-toxic prodrug into a toxic drug specifically at the tumor site.
Supporting Evidence
- The fusion protein retained antibody specificity and enzyme activity.
- It was able to convert a non-toxic prodrug to doxorubicin, resulting in cytotoxicity.
- A bystander effect was demonstrated, showing that doxorubicin was detected in all cells when only a fraction expressed the fusion protein.
Takeaway
Scientists created a special protein that can help turn a harmless medicine into a powerful cancer-fighting drug right where the tumor is, without hurting other parts of the body.
Methodology
The study involved constructing a fusion protein and testing its ability to activate a prodrug in cancer cells.
Limitations
The prodrug activation may not occur uniformly throughout the tumor tissue.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website